echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Haizheng pharmaceutical's performance in 2018 is expected to lose 400-500 million yuan!

    Haizheng pharmaceutical's performance in 2018 is expected to lose 400-500 million yuan!

    • Last Update: 2019-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On January 31, Haizheng Pharmaceutical Co., Ltd issued the announcement of 2018 annual performance pre loss According to the preliminary calculation by the financial department of Zhejiang Haizheng Pharmaceutical Co., Ltd., it is estimated that the net profit attributable to the shareholders of the listed company in 2018 will be loss compared with 13.5662 million yuan in the same period of last year, and the net profit loss attributable to the shareholders of the listed company will be 410 million yuan to 500 million yuan It is estimated that the net profit loss attributable to the shareholders of the listed company after deducting the non recurring profit and loss is 520 million yuan to 620 million yuan The announcement shows that there are two main reasons for the pre loss of performance: (1) the main business impact: 1 The lifting of EU market ban of API products is later than expected, the sales of high margin products of API in European and American markets have declined, and the gross margin of API has declined about 150 million yuan year-on-year; 2 The company adjusts the R & D direction and strategy, and confirms to suspend or suspend the development of some R & D projects, including some of the R & D projects that have been capitalized, which no longer meet the capitalization conditions It is estimated that the amount of the project to be transferred to expense is 130-190 million yuan; 3 The company sorted out and evaluated the projects under construction, and decided to stop the follow-up construction of individual production lines inconsistent with the market demand It is estimated that the part of the projects under construction will be impaired, and the provision for impairment is expected to be RMB 50-75 million (2) The impact of non operating profit and loss on the company's non operating income decreased Pfizer's compensation of US $15 million due to insufficient supply compared with the same period last year Original announcement attached:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.